The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| BLFS | +20.3% | -3.15% | -0.64% | -95% |
| S&P | +15.06% | +95.03% | +14.29% | +1,533% |
BioLife Solutions, Inc. engages in the development, manufacture and marketing of bio preservation tools for cells and tissues. Its product offerings include proprietary hypothermic storage and cryopreservation freeze media products for cells, tissues, and organs, generic blood stem cell freezing and cell thawing media products and custom product formulation and custom packaging services. The company was founded by Boris Rubinsky in 1987 and is headquartered in Bothell, WA.
The company saw revenue decline, year over year, in the second quarter.
The company reported declining revenue and reduced annual guidance.
| Q2 2025 | YOY Change | |
|---|---|---|
| Revenue | $25.42M | -10.3% |
| Gross Profit | $15.73M | 12.5% |
| Gross Margin | 61.86% | 12.5% |
| Market Cap | $1.02B | 3.8% |
| Market Cap / Employee | $6.44M | 0.0% |
| Employees | 159 | -61.6% |
| Net Income | -$15.84M | -121.6% |
| EBITDA | -$15.26M | -3863.9% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q2 2025 | YOY Change | |
|---|---|---|
| Net Cash | $31.90M | 44.7% |
| Accounts Receivable | $10.06M | -44.3% |
| Inventory | 27.7 | -14.8% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $11.60M | -48.5% |
| Short Term Debt | $12.22M | -9.1% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -5.25% | 9.6% |
| Return On Invested Capital | -8.68% | 2.7% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | $5.63M | 2.9% |
| Operating Free Cash Flow | $7.37M | 14.1% |
| Metric | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Book | 3.56 | 3.69 | 3.07 | 2.90 | -1.10% |
| Price to Sales | 9.37 | 11.00 | 10.20 | 10.03 | 28.31% |
| Price to Tangible Book Value | 14.06 | 14.58 | 8.43 | 7.79 | -29.64% |
| Price to Free Cash Flow TTM | 204.61 | 239.61 | 92.91 | 87.64 | - |
| Enterprise Value to EBITDA | 1531.83 | -1304.25 | 6114.01 | -63.67 | -97.52% |
| Free Cash Flow Yield | 0.5% | 0.4% | 1.1% | 1.1% | - |
| Return on Equity | -9.9% | -6.1% | -3.3% | -6.0% | -66.36% |
| Total Debt | $39.27M | $30.17M | $26.95M | $23.82M | -33.77% |
BLFS earnings call for the period ending September 30, 2021.
BLFS earnings call for the period ending June 30, 2021.
BLFS earnings call for the period ending March 31, 2021.
BLFS earnings call for the period ending December 31, 2020.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
